Dublin, Ireland, May 23rd, 2011 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of a new Cytometry Services offering from its Central Laboratories business unit. ICON Cytometry Services now offers clients two types of services to better support the testing requirements and development phase of a client’s compound.
ICON Cytometry Services’ full service solution allows clients to collaborate with ICON at the early stages of development to create compound-specific assays. Clients work with ICON Central Laboratories’ R&D team to develop a unique Flow Cytometry methodology, customised SOPs and agree on other special requirements including reporting. These customised Flow Cytometry panels can then be used throughout the compound development lifecycle. ICON Cytometry Services’ other service offering enables clients to choose from a wide range of fully validated assays and is often suited to the large scale, high-volume requirements of later phase global trials.
Commenting on the announcement, Tom O’Leary, President, ICON Central Laboratories, said, “Flow Cytometry has become a preferred testing method for many of our clients, particularly those with autoimmune, oncology and immunodeficiency compounds that require more specialised testing. Our new Cytometry Services offering provides clients with a better range of options, all of which are supported by a team of highly experienced scientists, robust instrumentation and rigorous quality control systems.”
ICON Central Laboratories offers global Flow Cytometry services from its laboratories in New York, Dublin, Bangalore and Singapore.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,800 employees, operating from 77 locations in 38 countries.
Further information is available at www.iconplc.com
Contacts
Weber Shandwick
Genevieve Tuck
gtuck@webershandwick.com
+44 (0) 2070 670 655
